Title: Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree
of malignant esophageal stenosis
Version: 1 Date: 22 Jul 2023
Reviewer's report:
The authors assessed the relationship between the improvement in MES and chemotherapy
regimen in patients who received preoperative FP or DCF therapy for the treatment of ESCC.
This manuscript is well written and informative, and the conclusion is acceptable. I have some
comments for this manuscript.
1) As the authors have stated, the value of this paper will increase if the relationship between
the dysphagia score and the stenosis index (SI) is shown.
2) In the DCF group, there were more advanced cases, but unlike the JCOG1109 results, the
DCF group showed a lower OS. Is it possible to consider other factors, such as decreased
chemotherapy compliance due to adverse events?
Title: Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree
of malignant esophageal stenosis
Version: 1 Date: 22 Jul 2023
Reviewer's report:
The authors assessed the relationship between the improvement in MES and chemotherapy
regimen in patients who received preoperative FP or DCF therapy for the treatment of ESCC.
This manuscript is well written and informative, and the conclusion is acceptable. I have some
comments for this manuscript.
1) As the authors have stated, the value of this paper will increase if the relationship between
the dysphagia score and the stenosis index (SI) is shown.
2) In the DCF group, there were more advanced cases, but unlike the JCOG1109 results, the
DCF group showed a lower OS. Is it possible to consider other factors, such as decreased
chemotherapy compliance due to adverse events?
Please review this paper.
user
Title: Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree
of malignant esophageal stenosis
Version: 1 Date: 22 Jul 2023
Reviewer's report:
The authors assessed the relationship between the improvement in MES and chemotherapy
regimen in patients who received preoperative FP or DCF therapy for the treatment of ESCC.
This manuscript is well written and informative, and the conclusion is acceptable. I have some
comments for this manuscript.
1) As the authors have stated, the value of this paper will increase if the relationship between
the dysphagia score and the stenosis index (SI) is shown.
2) In the DCF group, there were more advanced cases, but unlike the JCOG1109 results, the
DCF group showed a lower OS. Is it possible to consider other factors, such as decreased
chemotherapy compliance due to adverse events?
assistant